National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Myelodysplastic Syndromes Treatment (PDQ®)     
Last Modified: 10/08/2009
Health Professional Version
Changes to This Summary (10/08/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview 1

Revised text 2 to state that results have been reported from a phase III randomized controlled trial of 5-azacitidine versus other regimens (cited Fenaux et al. as reference 23).

Added text 3 on preliminary results reported from a phase III randomized controlled trial of decitabine versus best supportive care in higher-risk patients with myelodysplastic syndromes (cited WijerMans et al. as reference 26 and level of evidence 1iiA).



Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessi
onal/21.cdr#Section_21
2http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessi
onal/175.cdr#Section_175
3http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/HealthProfessi
onal/186.cdr#Section_186